FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Medical Devices

FDA Grants Breakthrough Device for AI Pathology

FDA grants Paige.AI a breakthrough device designation for its artificial intelligence tools to help physicians diagnose and treat cancer.

Human Drugs

MDIC Issues Landscape Analysis Report

The Medical Device Innovation Consortium releases a somatic reference sample landscape analysis report.

Human Drugs

3rd Circuit Fosamax Decision Affecting Other Cases: Attorney

Attorney Eric Alexander says a 3rd Circuit Court of Appeals decision in Fosamax that has been appealed to the Supreme Court is having an impact in oth...

Human Drugs

8 Observations in Brookfield Supply FDA-483

FDA releases the FDA-483 issued following an inspection at Brookfield Medical/Surgical Supply.

Human Drugs

Allergan sBLAs for Pediatric Limb Spasticity

FDA accepts two Allergan supplemental BLAs to expand its Botox (onabotulinumtoxin A)label for treating pediatric patients with upper and lower limb sp...

Human Drugs

Rapastinel Phase 3 Trials Missed Endpoints

Allergan says Phase 3 trials of its rapastinel as an adjunctive therapy for major depressive disorder failed to meet primary and key secondary endpoin...

Human Drugs

Genentech sNDA for Xofluza Expanded Use

FDA accepts for review a Genentech supplemental NDA for Xofluza (baloxavir marboxil) as a single-dose, oral treatment for people at high risk of compl...

Medical Devices

Zoll LifeVest Defibrillator Software Update

FDA updates a safety alert that warned health professionals about Zoll Medicals Zoll LifeVest 4000 Wearable Cardioverter Defibrillator due to concerns...

Federal Register

510(k) Exemption Proposed for Flow Cytometer Instruments

Federal Register notice: FDA seeks comments on its announced intention to exempt certain flow cytometer instruments from premarket notification requir...

Human Drugs

Better Non-efficacy Benefit Communication Needed: Analysis

Researchers say drug sponsors and FDA can do a better job of communicating non-efficacy benefits arising from non-inferiority trials.